Clinical trials: Controlled Diabetes
Type 1 Diabetes Mellitus
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting…
- Trial name
- NCT04476472
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Insulet Corporation
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2…
- Trial name
- SURMOUNT-5 (NCT05822830)
- Testing
- Tirzepatide, Semaglutide
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Type1 Diabetes Mellitus
A Pilot Test of t:Slim X2 With Control-IQ Technology
A 36-48 hour admission testing the t:slim X2 with Control-IQ Technology
- Trial name
- NCT03368937
- Testing
- Tandem t:slim X2 with Control-IQ Technology
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to…
- Trial name
- NCT01210001
- Testing
- BI 10773
- Where
- 68 sites in United States, Canada and 5 more
- Volunteers
- 499 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
- Trial name
- NCT00849017
- Testing
- albiglutide, albiglutide uptitration
- Where
- 262 sites in United States, Mexico and 1 more
- Volunteers
- 309 people
- Sponsor
- GlaxoSmithKline
Painful Diabetic Neuropathy, Diabetic Neuropathy
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
The purpose of the study is to determine whether clonidine gel is an effective treatment for reducing the pain associated with painful diabetic neuropathy.
- Conditions
- Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
- Trial name
- NCT02068027
- Testing
- Clonidine Gel 0.1%
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- BioDelivery Sciences International
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin.
- Trial name
- NCT01098539
- Testing
- albiglutide, sitagliptin
- Where
- 218 sites in United States, Australia and 13 more
- Volunteers
- 507 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes.
- Trial name
- NCT00972322
- Testing
- MK-8245
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00962065
- Testing
- LX4211 Low Dose, LX4211 High Dose
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus Type 2 With Hyperglycemia
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.
- Trial name
- NCT02303405
- Testing
- Hydroxychloroquine, Pioglitazone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Charles Drew University of Medicine and Science
Obesity and Diabetes Mellitus, Type 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from…
- Trial name
- NCT03586830
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 27 sites in United States
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.